METiS Entered into a License Agreement with Voronoi to Develop and Commercialize Pan-RAF Inhibitor Program
Shots:
- Voronoi to receive ~$1.7M up front & success-based near-term discovery milestones & is also eligible to receive ~$480.5M in development, regulatory, and sales milestones along with royalties on annual net sales
- Additionally, METiS to get an exclusive license to develop and commercialize Voronoi’s pan-RAF inhibitor program globally for class II & III BRAF mutant cancer patients with CNS metastasis
- AiTEM platform offers a strong proof-of-concept potential to enhance compound PK and create a distinctive profile, incl. CNS penetration. Through the combination of drug discovery and delivery with AI, machine learning, and quantum simulation, METiS will deliver the therapies across a wide range of disease areas
Ref: Businesswire | Image: METiS
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
